36 results
Thumbnail

D1.466 - Atopic dermatitis increases the risk of chronic systemic diseases in children and adolescents: a nationwide nested case–control study

Thumbnail

D1.472 - Features of the intestinal microbiota composition in infants with allergy: comparison of two diagnostic methods

Thumbnail

D1.473 - Features of the intestinal microbiota composition in infants with IgE- and non-IgE-mediated allergy

Thumbnail

D1.476 - Impact of neonatal vaccination on the incidence of atopic dermatitis in children by 36 months: a prospective cohort study

Thumbnail

D1.480 - Polysomnographic phenotypes of sleep-disordered breathing in children with asthma: a systematic review

Thumbnail

D1.467 - Economic Burden of Allergic Diseases in Children: Global Evidence and Implications for Kyrgyzstan

Thumbnail

D1.468 - Association Between Autism Spectrum Disorder and Skin Barrier Integrity

Thumbnail

D1.470 - Comparison of long-term (52 week therapy) maintenance vs. as-needed intranasal corticosteroid therapy in pediatric allergic rhinitis: assessment using exhaled breath condensate leukotriene E4

Thumbnail

D1.471 - From Grandmother to Granddaughter: A Case Report of Hereditary Angioedema Diagnosed in the Third Generation

Thumbnail

D1.475 - Significance of air-trapping and pulmonary hyperinflation in the severity of broncho-obstructive manifestations in children with cystic fibrosis

Thumbnail

D1.478 - Hyper-IgE in allergic bronchopulmonary aspergillosis: diagnostic challenges

Thumbnail

D1.479 - Lung function in children with cystic fibrosis associated with wheezing

Thumbnail

D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies

Thumbnail

D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection

Thumbnail

D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper

Thumbnail

D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials

Thumbnail

D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps

Thumbnail

D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use

Thumbnail

D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study

Thumbnail

D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD